Visannette is a hormonal preparation used for the treatment of endometriosis. This condition is one that may present with significant symptomatic burden.

---

What Visannette Treats: Main Uses and Benefits

This medication is commonly used to help with a range of symptoms related to this condition, including chronic, persistent pelvic pain and disruptive menstrual problems. Visannette is applicable within clinical settings that involve managing symptoms of endometriosis, including regular aches and deep discomfort, severe menstrual cramping (dysmenorrhea), and instances of abnormal or heavy menstrual bleeding. It is applied in clinical settings where supportive symptom management is appropriate, particularly during phases when symptoms become more noticeable and create noticeable functional strain.

Visannette contributes to easing the overall symptom load, and supports patients during episodes of heightened discomfort by offering symptomatic relief that may assist with coping more steadily with difficult episodes.

Quick Fact: Relief for Pelvic Pain Visannette is considered relevant for easing symptoms related to chronic pelvic discomfort and menstrual pain in women diagnosed with endometriosis.

Regulatory References

1. Visanne 2 mg tablets - Summary of Product Characteristics

Official Eligibility and Restrictions

Visannette (dienogest 2 mg) is officially documented for use in adult women and post-menarche adolescent females for the management of endometriosis-associated pelvic pain. Eligibility is strictly governed by regulatory criteria, defining groups who must not use the medicine (contraindications) and populations requiring special medical consideration.

---

Absolute Contraindications

Use of Visannette is prohibited for patients with the following conditions:

• Active Venous Thromboembolic Disorder (VTE): Including deep vein thrombosis or pulmonary embolism.
• Cardiovascular Disease: Past or present arterial and cardiovascular diseases (e.g., myocardial infarction, stroke).
• Severe Hepatic Disease or Tumors: Present or past severe liver disease (if function values are not normalized) or liver tumors (benign or malignant).
• Malignancies: Known or suspected sex hormone-dependent cancers.
• Pregnancy and Lactation: Known or suspected pregnancy, or while breastfeeding.
• Undiagnosed Bleeding: Undiagnosed abnormal genital bleeding.

---

Age-Related and Conditional Use

Population Group	Eligibility Status
Children (Pre-Menarche)	Not indicated for use.
Adolescents (Post-Menarche)	Use is permitted, but requires careful benefit/risk evaluation.
Geriatric Population	No relevant use or indication established.
Renal Impairment	No adjustment suggested, though not specifically studied.

Patients with conditions such as a history of depression or specific hereditary metabolic disorders (like galactose intolerance) require careful observation or avoidance, as detailed in the official prescribing information.

Interactions with other medicines and products

Visannette (dienogest) is primarily metabolized by the cytochrome P450 3A4 (CYP3A4) enzyme system in the liver. As a result, its therapeutic effects or safety profile can be altered when co-administered with other products that affect this enzyme.

Impact on Visannette Levels

Mechanism	Effect on Visannette Concentration	Examples of Interacting Products
Enzyme Induction	Significantly decreased (reduced efficacy)	Medicines for epilepsy (e.g., phenytoin, carbamazepine, phenobarbital), rifampicin (for tuberculosis), and the herbal product St. John's wort.
Enzyme Inhibition	Significantly increased (potential toxicity)	Azole antifungals (e.g., ketoconazole, itraconazole), macrolide antibiotics (e.g., erythromycin, clarithromycin), and certain HIV/HCV protease inhibitors (e.g., ritonavir, indinavir).

Other Constraints

It is important to note that Visannette is not a contraceptive. The use of any form of hormonal contraceptive (including oral tablets, patches, or rings) must be avoided while taking this medicine. If pregnancy prevention is desired, non-hormonal barrier methods should be used. Additionally, Visannette may interfere with the results of certain laboratory tests, possibly affecting measurements of liver function or thyroid parameters.

How Visannette Works: Mechanism of Action

The mechanism of Dienogest is defined by a dual pharmacological approach that simultaneously acts at the central hormonal level and directly within the target tissue, leading to a distinct physiological consequence.

---

Direct Action: Progesterone Receptor Agonism and Tissue Atrophy

Dienogest acts as a selective, high-affinity agonist (activator) of the Progesterone Receptor (PR) within the target tissue cells. This sustained activation initiates a molecular cascade resulting in the specialized transformation known as decidualization. This tissue transformation is immediately followed by atrophy (shrinkage), which is the primary physiological mechanism for the reduction of the target tissue mass.

---

Supportive Mechanism: HPO Axis Modulation and Hypoestrogenism

A secondary, supportive mechanism involves the moderate suppression of the Hypothalamic-Pituitary-Ovarian (HPO) axis. This central action reduces the release of gonadotropins, which, in turn, decreases the body's production of endogenous estrogen. The resulting low-estrogen environment is established because it reduces proliferative signaling to the target tissue, thereby supporting the local atrophic effect.

---

Local Anti-Growth Effects: Angiogenesis and Inflammation Regulation

In addition to its hormonal effects, Dienogest modulates the local tissue microenvironment. It inhibits factors involved in tissue vascularization, such as VEGF, leading to anti-angiogenesis (reduced blood vessel growth), and dampens pro-inflammatory cytokine signaling. These local anti-growth mechanisms contribute to limiting the tissue’s vascular supply and inflammatory drive, contributing to the tissue's ongoing regression.

Administration and Dosing Principles

Visannette is administered exclusively via the oral route as a 2 mg dienogest tablet. The dosing regimen requires taking one tablet daily. The primary principle of use is continuous administration without a tablet-free interval. A new pack must be started immediately after finishing the previous one, independent of any vaginal bleeding.

Schedule and Contextual Instructions

To ensure consistent exposure, the tablet should be taken preferably at the same time each day, though it can be taken with or without food. Treatment initiation may begin on any day of the menstrual cycle.

In the event of a missed dose, the instruction is to take only one tablet as soon as the lapse is remembered, then resume the next tablet at the usual scheduled time. If the tablet is not fully absorbed due to vomiting or severe diarrhea within three to four hours of ingestion, a single replacement tablet should be taken. A crucial administration constraint is the requirement that all hormonal contraceptives be discontinued before starting treatment with Visannette.

Research Evidence / Overview of Studies for Visannette

---

Evidence for Managing Endometriosis-Associated Pain

Research on Visannette for endometriosis-associated pain primarily involves short-term Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms in women of reproductive age who had confirmed endometriosis. Researchers examined patient-reported experiences related to physical discomfort, focusing on outcomes such as general pelvic pain intensity, as well as specific outcomes like severe menstrual cramping (dysmenorrhea) and painful intercourse (dyspareunia). Studies monitored how symptoms evolved in the observed populations over defined time intervals.

Studies comparing Visannette to placebo over periods typically lasting 12 to 24 weeks evaluated outcomes related to pain measurement. Research describes changes measured during the study period, relevant in evidence describing how symptoms are measured in conditions characterized by fluctuating or episodic manifestations. Research explored whether patient-reported outcomes describing perceived discomfort and functional activity levels were associated with the medication across the short-term duration of the trials.

---

Evidence for Post-Surgical Recurrence Prevention

Visannette was studied following conservative surgery to remove endometriosis lesions. Research examined the use of the medicine in post-operative settings and monitored outcomes related to the recurrence of endometriosis. Studies included women who had undergone laparoscopic surgery and focused on two main outcomes: the rate of disease recurrence (return of visible lesions, often defined by imaging) and the rate of painful symptom recurrence. Evidence in this area is derived mainly from Systematic Reviews and Meta-analyses that consolidate findings from controlled observational studies.

Studies focusing on episodes where symptoms become more noticeable reported how symptoms evolved in the observed populations when compared to control groups. Findings describe patterns observed in the studies related to the return of painful symptoms and the incidence rate of recurrent lesions. This research provides context, but it is important to note that the findings were often pooled from studies with varying designs and comparator groups, which can introduce heterogeneity in reported outcomes.

---

What Remains Unclear or Requires More Research

A primary limitation of the current evidence is that long-term effects are not fully established by dedicated, prospective, comparative trials lasting several years. Research highlights changes measured during the study period, but the durability of these patterns after stopping the medicine, or during extended continuous use, requires further investigation. Comparative evidence is lacking for a comprehensive, head-to-head evaluation against all other current hormonal treatments. The evidence helps show what has been observed so far, but research does not determine whether an individual will respond similarly.

Key Studies & References

1. Visanne 2 mg tablets - Summary of Product Characteristics (SPC) - Health Products Regulatory Authority (HPRA) Ireland
2. Dienogest, a selective progesterone receptor agonist, reduces endometriosis recurrence after surgery (Kim et al., 2011)

Common questions about Visannette (FAQ)

Q: What kind of mood changes, anxiety, or irritability are officially associated with Visannette?

A: Regulatory documents list several common side effects related to mood and the nervous system. These documented effects can include depressed mood, nervousness, and irritability. Official safety information includes warnings that changes in emotional well-being may occur.

Q: Is a decrease in bone mineral density (BMD) associated with Visannette use?

A: Official safety constraints note that a decrease in Bone Mineral Density (BMD), a measure of bone strength, has been observed in adolescent patients (ages 12-18) treated for 12 months. For adults, the long-term impact on BMD is still being examined. This finding indicates that use in younger patients requires specialized consideration.

Q: What are the reported effects of Visannette on skin pigmentation, such as chloasma?

A: Official product information indicates that chloasma, which appears as golden-brown patches on the skin, may occur occasionally. This is noted to happen more often in individuals who have a history of chloasma during pregnancy. Regulatory documents note that avoiding excessive sun exposure or other sources of UV light is recommended.

Q: What are the serious, but less common, side effects mentioned in official documents?

A: While rare, regulatory safety information includes warnings about serious adverse reactions. These documented risks include Venous Thromboembolism (VTE), which involves blood clots forming in the veins, and the very rare occurrence of liver tumors (which can be benign or malignant). The official product information also mentions the possibility of persistent ovarian follicles, commonly known as ovarian cysts.

Q: Can grapefruit juice interact with Visannette and increase the risk of side effects?

A: Yes, regulatory documents note that grapefruit juice is a strong inhibitor of the CYP3A4 enzyme system. Co-administration may lead to an increase in the concentration of Visannette in the body, which could potentially result in undesirable effects.

Q: Does Visannette contain lactose or other ingredients that might be a concern for some users?

A: The tablet formulation officially lists lactose monohydrate as an inactive ingredient, or excipient. This information is relevant to patients with certain hereditary metabolic disorders, such as galactose intolerance.

Q: How soon after starting Visannette can a patient expect to feel pain relief?

A: Clinical trials reviewed by regulatory bodies indicate that pain associated with endometriosis typically starts to decrease over time as treatment continues. Pain reduction has been measured and observed over the course of several months of continuous treatment.

Q: What is the typical rate of symptom recurrence after stopping Visannette?

A: Clinical research has specifically monitored outcomes related to the return of painful symptoms after the completion of treatment. However, official summaries do not provide a standardized or typical recurrence rate, as the findings can differ depending on the specific study and patient population examined.

Q: Why is calcium and Vitamin D intake sometimes mentioned with Visannette use?

A: The official safety note regarding the potential for a decrease in bone mineral density, especially in adolescents, is the reason for this mention. Regulatory guidance suggests that measures to support bone health, such as ensuring adequate intake of bone-supporting nutrients like calcium and vitamin D, should be considered in the context of this potential risk.

Q: Is Visannette also used to manage conditions other than endometriosis?

A: The official therapeutic indication for Visannette (the specific 2 mg dienogest monotherapy tablet) is exclusively for the treatment of endometriosis. The official regulatory indication for Visannette is exclusively for the treatment of endometriosis.

Q: Can Visannette be used for endometriosis pain management without surgery?

A: Yes, Visannette is indicated for the treatment of endometriosis, which includes managing pelvic pain associated with the lesions. It is a recognized therapeutic option.

Q: Is unusual fatigue or tiredness a recognized side effect?

A: Official regulatory documents list unusual weakness or generalized weakness as a common side effect of the medicine. These types of effects are grouped under the list of frequently reported issues observed in patients.

Q: Can Visannette affect other non-hormonal painkillers?

A: Based on laboratory studies, it is considered unlikely that Visannette would cause a clinically relevant interaction with the process by which most other non-hormonal medicines are metabolized (broken down) in the body.

Q: Is there a safety notice for Visannette use in patients with diabetes?

A: Yes, regulatory documents advise that Visannette may have a slight influence on the body's sensitivity to insulin or its tolerance for glucose. Official guidance states that diabetic women, especially those with a history of gestational diabetes, require careful observation during treatment.

Q: What are the consequences of taking Visannette for several years?

A: Official documents note that the complete long-term effects of continuous use lasting several years have not been fully established by dedicated prospective research. There is limited experience and a lack of comparative trial data for continuous use lasting longer than 15 months for all populations.

Q: Is it necessary to use a backup contraceptive method with Visannette for pregnancy prevention?

A: Yes. Visannette is not approved or intended for use as a contraceptive. The official guidance is that non-hormonal methods of contraception (such as barrier methods) are required if pregnancy prevention is desired, as Visannette is not a contraceptive.

Q: Can Visannette be used by women who have gone through menopause?

A: The official indication for Visannette is for women of reproductive age. Regulatory documents state there is no relevant use or indication established for the geriatric population, which generally applies to post-menopausal women.

Q: What are the limitations of the existing research evidence for Visannette?

A: Official research overviews highlight several limitations. These include a lack of dedicated, prospective comparative trials for very long-term use and a lack of comprehensive, head-to-head evaluation against all other current hormonal treatment options for this condition.

Q: What is the relationship between Visannette and the risk of breast cancer?

A: The official regulatory text establishes a clear restriction: Visannette is contraindicated (must not be used) in patients with a known or suspected sex hormone-dependent malignancy, such as breast cancer.

Q: What is the rate of disease recurrence (return of visible lesions) after stopping Visannette?

A: Clinical research has monitored outcomes related to the recurrence of visible endometriosis lesions after surgical removal and subsequent treatment. However, the official summaries of these studies do not provide a simple, standardized recurrence rate percentage for all patients.

Official Storage and Disposal Instructions for Visannette

Visannette (dienogest 2 mg tablets) must be stored according to official regulatory requirements to maintain product integrity and safety.

Storage Conditions

The required storage temperature is below 30°C in a cool, dry place. The medicine must be kept in its original blister pack until the time of use and must be kept out of the sight and reach of children. Prohibited environments include damp locations, such as bathrooms, or places subject to heat, like window sills or cars. Do not use the tablets after the expiry date, or if the packaging is torn or shows signs of tampering.

Disposal Instructions

Official disposal rules require that any unused, expired, or compromised medicine be returned to a pharmacist for proper pharmaceutical waste management. Do not dispose of the tablets in household waste or wastewater.